Patents by Inventor Antonella Converso
Antonella Converso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043402Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: December 6, 2021Publication date: February 8, 2024Applicant: Merck Sharp & Dohme LLCInventors: Antonella Converso, David N. Hunter, Abdellatif El Marrouni, Anthony J. Roecker, Anthony W. Shaw, William D. Shipe, Cheng Wang, Deping Wang, Yunlong Zhang
-
Publication number: 20230357204Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: August 25, 2021Publication date: November 9, 2023Applicant: Merck Sharp & Dohme LLCInventors: Antonella Converso, Abdellatif El Marrouni, Anthony W. Shaw, David N. Hunter, Ashley Forster, Cheng Wang, Yunlong Zhang
-
Patent number: 11648250Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: GrantFiled: August 25, 2021Date of Patent: May 16, 2023Assignee: Merck Sharp & Dohme LLCInventors: Antonella Converso, Abdellatif El Marrouni, Anthony W. Shaw, David N. Hunter, Ashley Forster, Cheng Wang, Yunlong Zhang
-
Publication number: 20220242847Abstract: The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: May 18, 2020Publication date: August 4, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Cheng Wang, Deping Wang
-
Publication number: 20220062284Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: August 25, 2021Publication date: March 3, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Abdellatif El Marrouni, Anthony W. Shaw, David N. Hunter, Ashley Forster, Cheng Wang, Yunlong Zhang
-
Publication number: 20220064147Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: December 13, 2019Publication date: March 3, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Scott D. Kuduk, Helen J. Mitchell, Philippe Nantermet, Deyou Sha, William Daniel Shipe, Cheng Wang, Deping Wang
-
Patent number: 10376504Abstract: The present invention is directed to azacyanoquinolinone compounds of the general structural formula: (wherein R5 and R6 are defined herein) which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: July 27, 2016Date of Patent: August 13, 2019Assignee: Merck, Sharp & Dohme Corp.Inventors: Antonella Converso, Kevin Rodzinak
-
Patent number: 10370337Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: July 27, 2016Date of Patent: August 6, 2019Assignee: Merck, Sharp & Dohme Corp.Inventors: Antonella Converso, Mildred L. Kaufman, Kevin Rodzinak
-
Patent number: 10370336Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: July 27, 2016Date of Patent: August 6, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Victoria Cofre, Antonella Converso, Kevin Rodzinak
-
Publication number: 20180258046Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: July 27, 2016Publication date: September 13, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: ANTONELLA CONVERSO, MILDRED L. KAUFMAN, KEVIN RODZINAK
-
Publication number: 20180214439Abstract: The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: July 27, 2016Publication date: August 2, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: ANTONELLA CONVERSO, KEVIN RODZINAK
-
Publication number: 20180208557Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: July 27, 2016Publication date: July 26, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: VICTORIA COFRE, ANTONELLA CONVERSO, KEVIN RODZINAK
-
Patent number: 9663506Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 18, 2016Date of Patent: May 30, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
-
Patent number: 9636337Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 18, 2016Date of Patent: May 2, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
-
Publication number: 20160159744Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 18, 2016Publication date: June 9, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
-
Publication number: 20160158217Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, including potentially Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 18, 2016Publication date: June 9, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
-
Patent number: 9278960Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 26, 2012Date of Patent: March 8, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher James Bungard, Antonella Converso, Barbara Hanney, Timothy John Hartingh, Peter J. Manley, Robert S. Meissner, James J. Perkins, Michael T. Rudd
-
Publication number: 20140309227Abstract: The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (I) wherein ring A, RQ, -L-, R1, n, R2, and R3 are as defined herein. The compounds of the invention are useful as non-competitive mGluR2 antagonists, or mGluR2 negative allosteric modulators (NAMs), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2012Publication date: October 16, 2014Inventors: Christopher James Bungard, Antonella Converso, Pablo De Leon, Barbara Hanney, Timothy John Hartingh, Jesse Josef Manikowski, Peter J. Manley, Robert Meissner, Zhaoyang Meng, James J. Perkins, Michael T. Rudd, Youheng Shu
-
Patent number: 8629275Abstract: The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.Type: GrantFiled: August 31, 2009Date of Patent: January 14, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Timothy J. Hartingh, Mark E. Fraley
-
Patent number: 8329697Abstract: The present invention is directed to AHCY inhibitors of formula (I) which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases characterized by high homocysteine levels.Type: GrantFiled: February 18, 2009Date of Patent: December 11, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Robert M. Garbaccio, Antonella Converso, Mark E. Fraley, Timothy J. Hartingh